Carmell (CTCX) Competitors

Inogen (NASDAQ:INGN) and Carmell (NASDAQ:CTCX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Which has preferable earnings and valuation, INGN or CTCX?

Carmell has lower revenue, but higher earnings than Inogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$335.70M	0.64	-$35.89M	-$1.06	-7.54
Carmell	$32.84K	1,718.79	-$15.44M	N/A	N/A

Is INGN or CTCX more profitable?

Carmell has a net margin of 0.00% compared to Inogen's net margin of -7.58%. Inogen's return on equity of -13.77% beat Carmell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-7.58%	-13.77%	-8.52%
Carmell	N/A	-217.50%	-50.22%

Do institutionals and insiders have more ownership in INGN or CTCX?

89.9% of Inogen shares are held by institutional investors. Comparatively, 24.2% of Carmell shares are held by institutional investors. 1.5% of Inogen shares are held by insiders. Comparatively, 29.0% of Carmell shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has more volatility & risk, INGN or CTCX?

Inogen has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Comparatively, Carmell has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Does the media favor INGN or CTCX?

In the previous week, Inogen had 1 more articles in the media than Carmell. MarketBeat recorded 1 mentions for Inogen and 0 mentions for Carmell. Inogen's average media sentiment score of 1.00 beat Carmell's score of 0.00 indicating that Inogen is being referred to more favorably in the media.

Company	Overall Sentiment
Inogen	Positive
Carmell	Neutral

Do analysts recommend INGN or CTCX?

Inogen currently has a consensus price target of $11.00, suggesting a potential upside of 37.67%. Given Inogen's stronger consensus rating and higher probable upside, analysts plainly believe Inogen is more favorable than Carmell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Carmell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Inogen beats Carmell on 10 of the 14 factors compared between the two stocks.